CRISM Therapeutics Corporation
CRTX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £5,285 | £837 | £461 | £1,597 |
| - Cash | £479 | £1,282 | £2,354 | £4,384 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £4,806 | -£445 | -£1,892 | -£2,787 |
| Revenue | £0 | – | £0 | £0 |
| % Growth | – | – | – | – |
| Gross Profit | -£4 | – | -£20 | £0 |
| % Margin | – | – | – | – |
| EBITDA | -£1,235 | – | £6 | -£293 |
| % Margin | – | – | – | – |
| Net Income | -£1,276 | – | -£16 | -£422 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.038 | – | -0.002 | 0.23 |
| % Growth | – | – | -100.9% | – |
| Operating Cash Flow | -£1,193 | £0 | -£592 | -£1 |
| Capital Expenditures | £0 | £0 | -£9 | £0 |
| Free Cash Flow | -£1,193 | £0 | -£601 | -£1 |